Literature DB >> 16047475

Nitric oxide-dependent osteopontin expression induces metastatic behavior in HepG2 cells.

Hongtao Guo1, Carlos E Marroquin, Philip Y Wai, Paul C Kuo.   

Abstract

Our objective was to delineate the role of nitric oxide (NO) in osteopontin (OPN)-associated metastatic properties in HepG2 cells. OPN is the major phosphoprotein secreted by malignant cells in patients with advanced metastatic cancer, is frequently overexpressed in human tumors, and has been implicated as a key mediator of tumor cell metastasis. OPN is significantly overexpressed in hepatocellular cancer (HCC) and correlates with capsular infiltration and behavior. In addition, significantly increased inducible nitric oxide synthase (iNOS) and NO expression are found in HCC. In archived human samples of normal, cirrhotic, and HCC livers, we demonstrate that iNOS and OPN protein are strongly coexpressed in hepatoma cells. In the setting of cirrhosis, hepatocytes express iNOS, but not OPN. Further in vitro studies performed with HepG2 hepatocellular cancer cells demonstrate that exogenous NO transcriptionally upregulates OPN expression. Enhanced expression of OPN in this setting is associated with increased in vitro cell adhesion and invasion. These data suggest that NO enhances HCC expression of OPN and, as a result, conveys a metastatic phenotype.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16047475     DOI: 10.1007/s10620-005-2775-6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  44 in total

1.  Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma.

Authors:  N Shijubo; T Uede; S Kon; M Maeda; T Segawa; A Imada; M Hirasawa; S Abe
Journal:  Am J Respir Crit Care Med       Date:  1999-10       Impact factor: 21.405

2.  Inducible nitric oxide synthase and survivin messenger RNA expression in hepatocellular carcinoma.

Authors:  Masahide Ikeguchi; Tsuyoshi Ueta; Yoshiaki Yamane; Yasuaki Hirooka; Nobuaki Kaibara
Journal:  Clin Cancer Res       Date:  2002-10       Impact factor: 12.531

3.  The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model.

Authors:  A J Oates; R Barraclough; P S Rudland
Journal:  Oncogene       Date:  1996-07-04       Impact factor: 9.867

4.  Osteopontin: possible role in prostate cancer progression.

Authors:  G N Thalmann; R A Sikes; R E Devoll; J A Kiefer; R Markwalder; I Klima; C M Farach-Carson; U E Studer; L W Chung
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

5.  Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling.

Authors:  Deepak Agrawal; Tingan Chen; Rosalyn Irby; John Quackenbush; Ann F Chambers; Marianna Szabo; Alan Cantor; Domenico Coppola; Timothy J Yeatman
Journal:  J Natl Cancer Inst       Date:  2002-04-03       Impact factor: 13.506

6.  Isolation of and effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line.

Authors:  H Chen; Y Ke; A J Oates; R Barraclough; P S Rudland
Journal:  Oncogene       Date:  1997-04-03       Impact factor: 9.867

Review 7.  The functional and clinical roles of osteopontin in cancer and metastasis.

Authors:  K A Furger; R K Menon; A B Tuck; V H Bramwell; A F Chambers
Journal:  Curr Mol Med       Date:  2001-11       Impact factor: 2.222

8.  Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts.

Authors:  H A Gardner; B Berse; D R Senger
Journal:  Oncogene       Date:  1994-08       Impact factor: 9.867

9.  Osteopontin expression and distribution in human carcinomas.

Authors:  L F Brown; A Papadopoulos-Sergiou; B Berse; E J Manseau; K Tognazzi; C A Perruzzi; H F Dvorak; D R Senger
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

10.  Osteopontin expression in a group of lymph node negative breast cancer patients.

Authors:  A B Tuck; F P O'Malley; H Singhal; J F Harris; K S Tonkin; N Kerkvliet; Z Saad; G S Doig; A F Chambers
Journal:  Int J Cancer       Date:  1998-10-23       Impact factor: 7.396

View more
  5 in total

1.  A mutant of hepatitis B virus X protein (HBx Delta 127) enhances hepatoma cell migration via osteopontin involving 5-lipoxygenase.

Authors:  Xuan Zhang; Li-hong Ye; Xiao-dong Zhang
Journal:  Acta Pharmacol Sin       Date:  2010-04-05       Impact factor: 6.150

Review 2.  Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers.

Authors:  Dong-Xing Cao; Zhi-Jie Li; Xiao-Ou Jiang; Yick Liang Lum; Ester Khin; Nikki P Lee; Guo-Hao Wu; John M Luk
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

3.  RNA stability regulates differential expression of the metastasis protein, osteopontin, in hepatocellular cancer.

Authors:  Sirisha Emani; Jinping Zhang; Lucie Guo; Hongtao Guo; Paul C Kuo
Journal:  Surgery       Date:  2008-04-18       Impact factor: 3.982

4.  iNOS Gene Ablation Prevents Liver Fibrosis in Leptin-Deficient ob/ob Mice.

Authors:  Sara Becerril; Amaia Rodríguez; Victoria Catalán; Beatriz Ramírez; Xabier Unamuno; Javier Gómez-Ambrosi; Gema Frühbeck
Journal:  Genes (Basel)       Date:  2019-02-27       Impact factor: 4.096

5.  Effect of thalidomide on the proliferation of hepatoma cells assessed by osteopontin levels in nude mice.

Authors:  Fan Lin; Jie Cao; Zhiming Huang; Zhenghao Pei; Weili Gu; Shaofeng Fan; Kunping Li; Jiefeng Weng
Journal:  Exp Ther Med       Date:  2013-03-15       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.